January 7, 2026 | Intelligent Commercialization
The MM+M Podcast features a conversation with Jamie Avallone, Chief Data Officer at Inizio Evoke, and Iris Lin, Product Science Lead at Inizio Evoke, who share their perspectives on what AI-powered audience intelligence means for life sciences organizations heading into 2026.

In the episode, they examine how life sciences companies are approaching AI and Large Language Models (LLMs), the challenges created by gaps in data sets, and why context and real behavior matter when predicting how healthcare professionals and patients engage.
The discussion focuses on several key themes, including:
Together, Jamie and Iris highlight how more precise, behavior-informed audience intelligence can support better decision-making as AI becomes increasingly central to life sciences marketing and engagement.
Listen to the full MM+M Podcast episode: “Beyond the algorithm: What AI-powered audience intelligence really means in 2026.”
This perspective is core to how Inizio delivers Intelligent Commercialization™ – our unified, expert-driven approach that connects proprietary data, technology, and AI to unlock measurable impact across the product lifecycle. Platforms such as Cognitev™ and Predictev™ (referenced in the discussion) translate over 35M hours of real-world behavior into actionable intelligence, enabling clients to anticipate shifts, optimize engagement, and make smarter decisions with confidence.
This content was provided by Inizio
Latest Content from Inizio
Conference Live gives you real-time insights, utilising the multimedia functionality of the smartphone in an innovative mobile app methodology. We conduct mobile conference research amongst physicians attending conferences, giving our clients…
The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.
A key feature of emerging markets is that patients often have to pay for a high proportion of their healthcare costs themselves. For all but the most severe conditions, public…
The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space…
Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain…
We look for bright and inquisitive people who want to learn in a company that’s pushing the boundaries of pharmaceutical market research
Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have won the prestigious Consultancy of the Year award at the 2016 Communiqué Awards in London. The judges…
Published in eyeforpharma July 2016 by Rachel Howard
Pegasus has expanded its pharma & life sciences senior team by appointing a new Associate Director and promoting two members of the existing team to Account Directors.
Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single…
